Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate

Pathobiology

Volumn 80, Issue 3, 2013, Pages 119-126

  Fujii, Tomomi ^a   Shimada, Keiji ^a   Asai, Osamu ^b   Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a   Hirao, Kazuya ^c   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Uda City Hospital   (Japan)

^c Hirao Hospital   (Japan)

Author keywords

CD204; CD68; Lymphocytes; Macrophages; Prostate carcinoma; Prostatitis

Indexed keywords

CD20 ANTIGEN; CD68 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; AGED; ARTICLE; B LYMPHOCYTE; BENIGN TUMOR; CANCER GROWTH; CARCINOGENESIS; CD3+ T LYMPHOCYTE; CELL INFILTRATION; GLEASON SCORE; HUMAN; HUMAN CELL; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE TUMOR; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR MICROENVIRONMENT;

EID: 84872272400     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000342396     Document Type: Article

References (29)

1. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121: 2381-2386.
2. Lu H, Ouyang W, Huang C: Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-233.
3. Konishi N, Nakamura M, Ishida E, Shimada K, Mitsui E, Yoshikawa R, Yamamoto H, Tsujikawa K: High expression of a new marker PCA-1 in human prostate carcinoma. Clin Cancer Res 2005; 11: 5090-5097.
4. Komohara Y, Ohnishi K, Kuratsu J, Takeya M: Possible involvement of the M2 antiinflammatory macrophage phenotype in growth of human gliomas. J Pathol 2008; 216: 15-24.
5. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S: Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011; 167:e211-e219.
6. Liu J, Li Z, Cui J, Xu G, Cui G: Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas. Tumour Biol 2012; 33: 495-505.
7. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, Nishimura M, Yoshida J, Takeyoshi I, Ochiai A: Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 2010; 5: 1507-1515.
8. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265.
9. Buddingh EP, Kuijjer ML, Duim RA, Bürger H, Agelopoulos K, Myklebost O, Serra M, Mertens F, Hogendoorn PC, Lankester AC, Cleton-Jansen AM: Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res 2011; 17: 2110-2119.
10. Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
11. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID: Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int 2001; 87: 797-805.
12. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K: Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 2002; 160: 1207-1214.
13. Shimada K, Matsuyoshi S, Nakamura M, Ishida E, Konishi N: Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. J Pathol 2005; 206: 423-432.
14. Shimada K, Nakamura M, Ishida E, Higuchi T, Tanaka M, Ota I, Konishi N: c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. Am J Pathol 2007; 171: 1003-1012.
15. Blumenfeld W, Tucci S, Narayan P: Incidental lymphocytic prostatitis: selective involvement with nonmalignant glands. Am J Surg Pathol 1992; 16: 975-981.
16. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE: Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66: 96-107.
17. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 2009; 59: 300-305.
18. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
19. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y: Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000; 7: 263-269.
20. Wang XY, Facciponte J, Chen X, Subjeck JR, Repasky EA: Scavenger receptor-A negatively regulates antitumor immunity. Cancer Res 2007; 67: 4996-5002.
21. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP: Evaluation of prostatitis in autopsied prostates -is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736-1740.
22. Doble A, Thomas BJ, Furr PM, Walker MM, Harris JR, Witherow RO, Taylor-Robinson D: A search for infectious agents in chronic abacterial prostatitis using ultrasound guided biopsy. Br J Urol 1989; 64: 297-301.
23. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL: Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995; 154: 407-413.
24. Nickel JC, Downey J, Young I, Boag S: Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-981.
25. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A: Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-1780.
26. Begley LA, Kasina S, MacDonald J, Macoska JA: The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43: 194-199.
27. Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, Lee V, Jin H, Wang M, Wright JA, Young AH: IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 2010; 59: 805-817.
28. McDowell KL, Begley LA, Mor-Vaknin N, Markovitz DM, Macoska JA: Leukocytic promotion of prostate cellular proliferation. Prostate 2010; 70: 377-389.
29. Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR: B regulatory cells and the tumor-promoting actions of TNF during squamous carcinogenesis. Proc Natl Acad Sci USA 2011; 108: 10662-10667.